Impact of the oral adsorbent AST-120 on organ-specific accumulation of uremic toxins: LC-MS/MS and MS imaging techniques

Toxins

Volumn 10, Issue 1, 2018, Pages

  Sato, Emiko ^a,b   Saigusa, Daisuke ^a   Mishima, Eikan ^b   Uchida, Taeko ^a   Miura, Daisuke ^c   Morikawa Ichinose, Tomomi ^c   Kisu, Kiyomi ^b   Sekimoto, Akiyo ^a,b   Saito, Ritsumi ^a   Oe, Yuji ^a   Matsumoto, Yotaro ^a   Tomioka, Yoshihisa ^a   Mori, Takefumi ^b   Takahashi, Nobuyuki ^a,b   Sato, Hiroshi ^a,b   Abe, Takaaki ^a   Niwa, Toshimitsu ^d   Ito, Sadayoshi ^b  

^a TOHOKU UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

^d SHUBUN UNIVERSITY   (Japan)

Author keywords

Chronic kidney disease; Indoxyl sulfate; Mass spectrometry; p cresyl sulfate; Uremic toxin

Indexed keywords

ADENINE; AST 120; CREATININE; INDICAN; PARA CRESYL SULFATE; UNCLASSIFIED DRUG; UREMIC TOXIN; 4-CRESOL SULFATE; CARBON; CRESOL; OXIDE; SULFATE; TOXIN;

ALBUMINURIA; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BIOCHEMICAL ANALYSIS; CONTROLLED STUDY; EXPERIMENTAL CHRONIC RENAL FAILURE; IMMUNOHISTOCHEMISTRY; KIDNEY FUNCTION; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOUSE; MUSCLE ATROPHY; NONHUMAN; ORGAN DYSFUNCTION SCORE; ORGAN WEIGHT; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; UREA NITROGEN BLOOD LEVEL; ADSORPTION; ANIMAL; C57BL MOUSE; CHRONIC KIDNEY FAILURE; DIAGNOSTIC IMAGING; LIQUID CHROMATOGRAPHY; METABOLISM; ORAL DRUG ADMINISTRATION; TANDEM MASS SPECTROMETRY; UREMIA;

ADMINISTRATION, ORAL; ADSORPTION; ANIMALS; CARBON; CHROMATOGRAPHY, LIQUID; CRESOLS; INDICAN; KIDNEY FAILURE, CHRONIC; MALE; MICE, INBRED C57BL; OXIDES; SULFURIC ACID ESTERS; TANDEM MASS SPECTROMETRY; TOXINS, BIOLOGICAL; UREMIA;

EID: 85040238782     PISSN: None     EISSN: 20726651     Source Type: Journal    
DOI: 10.3390/toxins10010019     Document Type: Article

References (51)

1. Barreto, F.C.; Barreto, D.V.; Liabeuf, S.; Drueke, T.B.; Massy, Z.A. Effects of uremic toxins on vascular and bone remodeling. Semin. Dial. 2009, 22, 433-437. [CrossRef] [PubMed]
2. Ellis, R.J.; Small, D.M.; Vesey, D.A.; Johnson, D.W.; Francis, R.; Vitetta, L.; Gobe, G.C.; Morais, C. Indoxyl sulphate and kidney disease: Causes, consequences and interventions. Nephrology 2016, 21, 170-177. [CrossRef] [PubMed]
3. Kazama, J.J.; Iwasaki, Y.; Fukagawa, M. Uremic osteoporosis. Kidney Int. Suppl. 2013, 3, 446-450. [CrossRef] [PubMed]
4. Liabeuf, S.; Drueke, T.B.; Massy, Z.A. Protein-bound uremic toxins: New insight from clinical studies. Toxins (Basel) 2011, 3, 911-919. [CrossRef] [PubMed]
5. Saito, S.; Yisireyili, M.; Shimizu, H.; Ng, H.Y.; Niwa, T. Indoxyl sulfate upregulates prorenin expression via nuclear factor-kappaB p65, signal transducer and activator of transcription 3, and reactive oxygen species in proximal tubular cells. J. Ren. Nutr. 2015, 25, 145-148. [CrossRef] [PubMed]
6. Adelibieke, Y.; Yisireyili, M.; Ng, H.Y.; Saito, S.; Nishijima, F.; Niwa, T. Indoxyl sulfate induces IL-6 expression in vascular endothelial and smooth muscle cells through OAT3-mediated uptake and activation of AhR/NF-kappaB pathway. Nephron Exp. Nephrol. 2014, 128, 1-8. [CrossRef] [PubMed]
7. Gelasco, A.K.; Raymond, J.R. Indoxyl sulfate induces complex redox alterations in mesangial cells. Am. J. Physiol. Ren. Physiol. 2006, 290, F1551-F1558. [CrossRef] [PubMed]
8. Gryp, T.; Vanholder, R.; Vaneechoutte, M.; Glorieux, G. p-Cresyl Sulfate. Toxins (Basel) 2017, 9, 52. [CrossRef] [PubMed]
9. Niwa, T. Role of indoxyl sulfate in the progression of chronic kidney disease and cardiovascular disease: Experimental and clinical effects of oral sorbent AST-120. Ther. Apher. Dial. 2011, 15, 120-124. [CrossRef] [PubMed]
10. Schroeder, J.C.; Dinatale, B.C.; Murray, I.A.; Flaveny, C.A.; Liu, Q.; Laurenzana, E.M.; Lin, J.M.; Strom, S.C.; Omiecinski, C.J.; Amin, S., et al. The uremic toxin 3-indoxyl sulfate is a potent endogenous agonist for the human aryl hydrocarbon receptor. Biochemistry 2010, 49, 393-400. [CrossRef] [PubMed]
11. Iwasaki, Y.; Yamato, H.; Nii-Kono, T.; Fujieda, A.; Uchida, M.; Hosokawa, A.; Motojima, M.; Fukagawa, M. Administration of oral charcoal adsorbent (AST-120) suppresses low-turnover bone progression in uraemic rats. Nephrol. Dial. Transplant. 2006, 21, 2768-2774. [CrossRef] [PubMed]
12. Koppe, L.; Pillon, N.J.; Vella, R.E.; Croze, M.L.; Pelletier, C.C.; Chambert, S.; Massy, Z.; Glorieux, G.; Vanholder, R.; Dugenet, Y., et al. p-Cresyl sulfate promotes insulin resistance associated with CKD. J. Am. Soc. Nephrol. 2013, 24, 88-99. [CrossRef] [PubMed]
13. Niwa, T. Update of uremic toxin research by mass spectrometry. Mass Spectrom. Rev. 2011, 30, 510-521. [CrossRef] [PubMed]
14. Sun, C.Y.; Chang, S.C.; Wu, M.S. Uremic toxins induce kidney fibrosis by activating intrarenal renin-angiotensin-aldosterone system associated epithelial-to-mesenchymal transition. PLoS ONE 2012, 7, e34026. [CrossRef] [PubMed]
15. Tanaka, H.; Iwasaki, Y.; Yamato, H.; Mori, Y.; Komaba, H.; Watanabe, H.; Maruyama, T.; Fukagawa, M. p-Cresyl sulfate induces osteoblast dysfunction through activating JNK and p38 MAPK pathways. Bone 2013, 56, 347-354. [CrossRef] [PubMed]
16. Yeh, Y.C.; Huang, M.F.; Liang, S.S.; Hwang, S.J.; Tsai, J.C.; Liu, T.L.; Wu, P.H.; Yang, Y.H.; Kuo, K.C.; Kuo, M.C., et al. Indoxyl sulfate, not p-cresyl sulfate, is associated with cognitive impairment in early-stage chronic kidney disease. Neurotoxicology 2016, 53, 148-152. [CrossRef] [PubMed]
17. Sato, E.; Mori, T.; Mishima, E.; Suzuki, A.; Sugawara, S.; Kurasawa, N.; Saigusa, D.; Miura, D.; Morikawa-Ichinose, T.; Saito, R., et al. Metabolic alterations by indoxyl sulfate in skeletal muscle induce uremic sarcopenia in chronic kidney disease. Sci. Rep. 2016, 6, 36618. [CrossRef] [PubMed]
18. Deguchi, T.; Ohtsuki, S.; Otagiri, M.; Takanaga, H.; Asaba, H.; Mori, S.; Terasaki, T. Major role of organic anion transporter 3 in the transport of indoxyl sulfate in the kidney. Kidney Int. 2002, 61, 1760-1768. [CrossRef] [PubMed]
19. Enoki, Y.; Watanabe, H.; Arake, R.; Sugimoto, R.; Imafuku, T.; Tominaga, Y.; Ishima, Y.; Kotani, S.; Nakajima, M.; Tanaka, M., et al. Indoxyl sulfate potentiates skeletal muscle atrophy by inducing the oxidative stress-mediated expression of myostatin and atrogin-1. Sci. Rep. 2016, 6, 32084. [CrossRef] [PubMed]
20. Motojima, M.; Hosokawa, A.; Yamato, H.; Muraki, T.; Yoshioka, T. Uremic toxins of organic anions up-regulate PAI-1 expression by induction of NF-kappaB and free radical in proximal tubular cells. Kidney Int. 2003, 63, 1671-1680. [CrossRef] [PubMed]
21. Sekine, T.; Watanabe, N.; Hosoyamada, M.; Kanai, Y.; Endou, H. Expression cloning and characterization of a novel multispecific organic anion transporter. J. Biol. Chem. 1997, 272, 18526-18529. [CrossRef] [PubMed]
22. Beischlag, T.V.; Luis Morales, J.; Hollingshead, B.D.; Perdew, G.H. The aryl hydrocarbon receptor complex and the control of gene expression. Crit. Rev. Eukaryot. Gene Expr. 2008, 18, 207-250. [CrossRef] [PubMed]
23. Niwa, T.; Emoto, Y.; Maeda, K.; Uehara, Y.; Yamada, N.; Shibata, M. Oral sorbent suppresses accumulation of albumin-bound indoxyl sulphate in serum of haemodialysis patients. Nephrol. Dial. Transplant. 1991, 6, 105-109. [CrossRef] [PubMed]
24. Schulman, G.; Vanholder, R.; Niwa, T. AST-120 for the management of progression of chronic kidney disease. Int. J. Nephrol. Renovasc. Dis. 2014, 7, 49-56. [CrossRef] [PubMed]
25. Nishikawa, M.; Ishimori, N.; Takada, S.; Saito, A.; Kadoguchi, T.; Furihata, T.; Fukushima, A.; Matsushima, S.; Yokota, T.; Kinugawa, S., et al. AST-120 ameliorates lowered exercise capacity and mitochondrial biogenesis in the skeletal muscle from mice with chronic kidney disease via reducing oxidative stress. Nephrol. Dial. Transplant. 2015, 30, 934-942. [CrossRef] [PubMed]
26. Yang, K.; Wang, C.; Nie, L.; Zhao, X.; Gu, J.; Guan, X.; Wang, S.; Xiao, T.; Xu, X.; He, T., et al. Klotho Protects Against Indoxyl Sulphate-Induced Myocardial Hypertrophy. J. Am. Soc. Nephrol. 2015, 26, 2434-2446. [CrossRef] [PubMed]
27. Cao, X.S.; Chen, J.; Zou, J.Z.; Zhong, Y.H.; Teng, J.; Ji, J.; Chen, Z.W.; Liu, Z.H.; Shen, B.; Nie, Y.X., et al. Association of indoxyl sulfate with heart failure among patients on hemodialysis. Clin. J. Am. Soc. Nephrol. 2015, 10, 111-119. [CrossRef] [PubMed]
28. Han, H.; Zhu, J.; Zhu, Z.; Ni, J.; Du, R.; Dai, Y.; Chen, Y.; Wu, Z.; Lu, L.; Zhang, R. p-Cresyl sulfate aggravates cardiac dysfunction associated with chronic kidney disease by enhancing apoptosis of cardiomyocytes. J. Am. Heart Assoc. 2015, 4, e001852. [CrossRef] [PubMed]
29. Rocha, B.; Ruiz-Romero, C.; Blanco, F.J. Mass spectrometry imaging: A novel technology in rheumatology. Nat. Rev. Rheumatol. 2017, 13, 52-63. [CrossRef] [PubMed]
30. Liu, H.; Li, W.; He, Q.; Xue, J.; Wang, J.; Xiong, C.; Pu, X.; Nie, Z. Mass Spectrometry Imaging of Kidney Tissue Sections of Rat Subjected to Unilateral Ureteral Obstruction. Sci. Rep. 2017, 7, 41954. [CrossRef] [PubMed]
31. Enomoto, A.; Takeda, M.; Tojo, A.; Sekine, T.; Cha, S.H.; Khamdang, S.; Takayama, F.; Aoyama, I.; Nakamura, S.; Endou, H., et al. Role of organic anion transporters in the tubular transport of indoxyl sulfate and the induction of its nephrotoxicity. J. Am. Soc. Nephrol. 2002, 13, 1711-1720. [CrossRef] [PubMed]
32. Deguchi, T.; Kusuhara, H.; Takadate, A.; Endou, H.; Otagiri, M.; Sugiyama, Y. Characterization of uremic toxin transport by organic anion transporters in the kidney. Kidney Int. 2004, 65, 162-174. [CrossRef] [PubMed]
33. Nii-Kono, T.; Iwasaki, Y.; Uchida, M.; Fujieda, A.; Hosokawa, A.; Motojima, M.; Yamato, H.; Kurokawa, K.; Fukagawa, M. Indoxyl sulfate induces skeletal resistance to parathyroid hormone in cultured osteoblastic cells. Kidney Int. 2007, 71, 738-743. [CrossRef] [PubMed]
34. Mishima, E.; Fukuda, S.; Mukawa, C.; Yuri, A.; Kanemitsu, Y.; Matsumoto, Y.; Akiyama, Y.; Fukuda, N.N.; Tsukamoto, H.; Asaji, K., et al. Evaluation of the impact of gut microbiota on uremic solute accumulation by a CE-TOFMS-based metabolomics approach. Kidney Int. 2017, 92, 634-645. [CrossRef] [PubMed]
35. Mishima, E.; Fukuda, S.; Shima, H.; Hirayama, A.; Akiyama, Y.; Takeuchi, Y.; Fukuda, N.N.; Suzuki, T.; Suzuki, C.; Yuri, A., et al. Alteration of the Intestinal Environment by Lubiprostone Is Associated with Amelioration of Adenine-Induced CKD. J. Am. Soc. Nephrol. 2014, 26, 1787-1794. [CrossRef] [PubMed]
36. Ramezani, A.; Massy, Z.A.; Meijers, B.; Evenepoel, P.; Vanholder, R.; Raj, D.S. Role of the Gut Microbiome in Uremia: A Potential Therapeutic Target. Am. J. Kidney Dis. 2016, 67, 483-498. [CrossRef] [PubMed]
37. Takayama, F.; Taki, K.; Niwa, T. Bifidobacterium in gastro-resistant seamless capsule reduces serum levels of indoxyl sulfate in patients on hemodialysis. Am. J. Kidney Dis. 2003, 41, S142-S145. [CrossRef] [PubMed]
38. Hida, M.; Aiba, Y.; Sawamura, S.; Suzuki, N.; Satoh, T.; Koga, Y. Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis. Nephron 1996, 74, 349-355. [CrossRef] [PubMed]
39. Meijers, B.K.; De Preter, V.; Verbeke, K.; Vanrenterghem, Y.; Evenepoel, P. p-Cresyl sulfate serum concentrations in haemodialysis patients are reduced by the prebiotic oligofructose-enriched inulin. Nephrol. Dial. Transplant. 2010, 25, 219-224. [CrossRef] [PubMed]
40. Kikuchi, M.; Ueno, M.; Itoh, Y.; Suda, W.; Hattori, M. Uremic Toxin-Producing Gut Microbiota in Rats with Chronic Kidney Disease. Nephron 2017, 135, 51-60. [CrossRef] [PubMed]
41. Yamamoto, S.; Kazama, J.J.; Omori, K.; Matsuo, K.; Takahashi, Y.; Kawamura, K.; Matsuto, T.; Watanabe, H.; Maruyama, T.; Narita, I. Continuous Reduction of Protein-Bound Uraemic Toxins with Improved Oxidative Stress by Using the Oral Charcoal Adsorbent AST-120 in Haemodialysis Patients. Sci. Rep. 2015, 5, 14381. [CrossRef] [PubMed]
42. Ishikawa, I.; Araya, M.; Hayama, T.; Sugano, M.; Yamato, H.; Ise, M. Effect of oral adsorbent (AST-120) on renal function, acquired renal cysts and aortic calcification in rats with adriamycin nephropathy. Nephron 2002, 92, 399-406. [CrossRef] [PubMed]
43. Owada, S.; Maeba, T.; Sugano, Y.; Hirayama, A.; Ueda, A.; Nagase, S.; Goto, S.; Nishijima, F.; Bannai, K.; Yamato, H. Spherical carbon adsorbent (AST-120) protects deterioration of renal function in chronic kidney disease rats through inhibition of reactive oxygen species production from mitochondria and reduction of serum lipid peroxidation. Nephron Exp. Nephrol. 2010, 115, e101-e111. [CrossRef] [PubMed]
44. Akizawa, T.; Asano, Y.; Morita, S.; Wakita, T.; Onishi, Y.; Fukuhara, S.; Gejyo, F.; Matsuo, S.; Yorioka, N.; Kurokawa, K. Effect of a carbonaceous oral adsorbent on the progression of CKD: A multicenter, randomized, controlled trial. Am. J. Kidney Dis. 2009, 54, 459-467. [CrossRef] [PubMed]
45. Schulman, G.; Berl, T.; Beck, G.J.; Remuzzi, G.; Ritz, E.; Arita, K.; Kato, A.; Shimizu, M. Randomized Placebo-Controlled EPPIC Trials of AST-120 in CKD. J. Am. Soc. Nephrol. 2015, 26, 1732-1746. [CrossRef] [PubMed]
46. Schulman, G.; Berl, T.; Beck, G.J.; Remuzzi, G.; Ritz, E.; Shimizu, M.; Shobu, Y.; Kikuchi, M. The effects of AST-120 on chronic kidney disease progression in the United States of America: A post hoc subgroup analysis of randomized controlled trials. BMC Nephrol. 2016, 17, 141. [CrossRef] [PubMed]
47. Jia, T.; Olauson, H.; Lindberg, K.; Amin, R.; Edvardsson, K.; Lindholm, B.; Andersson, G.; Wernerson, A.; Sabbagh, Y.; Schiavi, S., et al. A novel model of adenine-induced tubulointerstitial nephropathy in mice. BMC Nephrol. 2013, 14, 116. [CrossRef] [PubMed]
48. Fujii, H.; Nishijima, F.; Goto, S.; Sugano, M.; Yamato, H.; Kitazawa, R.; Kitazawa, S.; Fukagawa, M. Oral charcoal adsorbent (AST-120) prevents progression of cardiac damage in chronic kidney disease through suppression of oxidative stress. Nephrol. Dial. Transplant. 2009, 24, 2089-2095. [CrossRef] [PubMed]
49. Yang, J.; Caprioli, R.M. Matrix sublimation/recrystallization for imaging proteins by mass spectrometry at high spatial resolution. Anal. Chem. 2011, 83, 5728-5734. [CrossRef] [PubMed]
50. Takahashi, N.; Boysen, G.; Li, F.; Li, Y.; Swenberg, J.A. Tandem mass spectrometry measurements of creatinine in mouse plasma and urine for determining glomerular filtration rate. Kidney Int. 2007, 71, 266-271. [CrossRef] [PubMed]
51. Li, F.; Hagaman, J.R.; Kim, H.S.; Maeda, N.; Jennette, J.C.; Faber, J.E.; Karumanchi, S.A.; Smithies, O.; Takahashi, N. eNOS deficiency acts through endothelin to aggravate sFlt-1-induced pre-eclampsia-like phenotype. J. Am. Soc. Nephrol. 2012, 23, 652-660. [CrossRef] [PubMed]